BioRestorative Therapies CEO Mark Weinreb Interviewed on "Next Big Thing" with Financial Personality and Founder Tobin Smith

JUPITER, Fla., June 17, 2013 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTC BB: BRTX) – Financial personality and Founder of NBT Equities Research, Tobin Smith, recently interviewed BioRestorative Therapies, Inc. (the "Company") CEO, Mark Weinreb, on the firm's hybrid business model and what the firm is currently doing that will help change the biotechnology landscape. BioRestorative is a life sciences company focused on developing stem cell based cellular therapies for various personal medical applications.

NBT Equities Research interviews CEOs and industry leaders in the emerging growth sector and emerging growth sector advocacy groups to discuss trends and developments along with company updates.

Topics discussed by Mr. Weinreb include an update on the Company's ThermoStem™ Program designed to develop treatments using brown fat stem cells for metabolic disorders and obesity focused on potentially preventing the onset of Type 2 diabetes. Specifically, Mr. Weinreb shares the encouraging observation that it has made strides in preclinical development based on animal data.

In addition, Mr. Weinreb discusses the brtxDISC™ Program that encompasses a novel way of cell culturing and includes a medical device designed for the re-transplantation of an individual's own stem cells into the disc area for repair. This program is nearing readiness for clinical trials.

The interview can be heard on the NBT Equities Research website at the following link:
http://direct.nbtequitiesresearch.com/video/nbt-biorestorative-1

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:

• brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures.  This research is still in the non-clinical, investigational stage.
• ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
• brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin.  Potential cosmetic uses are being explored with third parties.

The Company also offers plant stem cell-based facial creams and beauty products under the Stem Pearls® brand at www.stempearls.com.

This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

Investor Contact:
Adam Holdsworth

ProActive Capital
646.862.4607
[email protected]

Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
[email protected]

SOURCE BioRestorative Therapies, Inc.